PMID- 34222013
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220424
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and 
      Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse 
      Large B-Cell Lymphoma After Second-Line Treatment Failure.
PG  - 687374
LID - 10.3389/fonc.2021.687374 [doi]
LID - 687374
AB  - OBJECTIVE: The prognosis for patients with relapsed or refractory diffuse large 
      B-cell lymphoma (R/R-DLBCL) after second-line treatment failure is extremely 
      poor. This study prospectively observed the efficacy and safety of decitabine 
      with a modified cisplatin, cytarabine, and dexamethasone (DHAP) regimen in 
      R/R-DLBCL patients who failed second-line treatment. METHODS: Twenty-one 
      R/R-DLBCL patients were enrolled and treated with decitabine and a modified DHAP 
      regimen. The primary endpoints were overall response rate (ORR) and safety. The 
      secondary endpoints were progression-free survival (PFS) and overall survival 
      (OS). RESULTS: ORR reached 50% (complete response rate, 35%), five patients (25%) 
      had stable disease (SD) with disease control rate (DCR) of 75%. Subgroup analysis 
      revealed patients over fifty years old had a higher complete response rate 
      compared to younger patients (P = 0.005), and relapsed patients had a better 
      complete response rate than refractory patients (P = 0.031). Median PFS was 7 
      months (95% confidence interval, 5.1-8.9 months). Median OS was not achieved. 
      One-year OS was 59.0% (95% CI, 35.5%-82.5%), and two-year OS was 51.6% (95% 
      confidence interval, 26.9%-76.3%). The main adverse events (AEs) were grade 3/4 
      hematologic toxicities such as neutropenia (90%), anemia (50%), and 
      thrombocytopenia (70%). Other main non-hematologic AEs were grade 1/2 
      nausea/vomiting (40%) and infection (50%). No renal toxicity or treatment-related 
      death occurred. CONCLUSION: Decitabine with a modified DHAP regimen can improve 
      the treatment response and prognosis of R/R-DLBCL patients with good tolerance to 
      AEs, suggesting this regimen has potential as a possible new treatment option for 
      R/R-DLBCL patients after second-line treatment failure. CLINICAL TRIAL 
      REGISTRATION: ClinicalTrials.gov, identifier: NCT03579082.
CI  - Copyright (c) 2021 Hu, Wang, Chen, Ding, Dong, Yang, Yin, Wu, Zhang, Fu, Sun, Li, 
      Wang, Li, Guo, Zhang, Lu, Leng, Zhang, Zhu, Zhang and Chen.
FAU - Hu, Junxia
AU  - Hu J
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Chen, Fei
AU  - Chen F
AD  - Medical School, Queen Mary School, Nanchang University, Nanchang, China.
FAU - Ding, Mengjie
AU  - Ding M
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Dong, Meng
AU  - Dong M
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Yang, Wanqiu
AU  - Yang W
AD  - Department of Oncology, The First Affiliated Hospital of Xinxiang Medical 
      University, Xinxiang, China.
FAU - Yin, Meifeng
AU  - Yin M
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Wu, Jingjing
AU  - Wu J
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhang, Lei
AU  - Zhang L
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Fu, Xiaorui
AU  - Fu X
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Sun, Zhenchang
AU  - Sun Z
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Li, Ling
AU  - Li L
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Wang, Xinhua
AU  - Wang X
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Li, Xin
AU  - Li X
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Guo, Shuangshuang
AU  - Guo S
AD  - Department of Oncology, The First Affiliated Hospital of Henan University of 
      Science and Technology, Luoyang, China.
FAU - Zhang, Dianbao
AU  - Zhang D
AD  - Department of Oncology, The First Affiliated Hospital of Henan University of 
      Science and Technology, Luoyang, China.
FAU - Lu, Xiaohui
AU  - Lu X
AD  - Lymphoma Hematopoietic Stem Cell Transplantation Center of the People's Hospital 
      of Jiaozuo City, Jiaozuo, China.
FAU - Leng, Qing
AU  - Leng Q
AD  - Department of Hematology, Anshan Central Hospital, Anshan, China.
FAU - Zhang, Mingzhi
AU  - Zhang M
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhu, Linan
AU  - Zhu L
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Zhang, Xudong
AU  - Zhang X
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Chen, Qingjiang
AU  - Chen Q
AD  - Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 
      Zhengzhou, China.
LA  - eng
SI  - ClinicalTrials.gov/NCT03579082
PT  - Journal Article
DEP - 20210618
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8253157
OTO - NOTNLM
OT  - chemotherapy
OT  - decitabine
OT  - diffuse large B cell lymphoma
OT  - modified DHAP regimen
OT  - safety
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/07/06 06:00
MHDA- 2021/07/06 06:01
PMCR- 2021/01/01
CRDT- 2021/07/05 10:13
PHST- 2021/03/29 00:00 [received]
PHST- 2021/05/31 00:00 [accepted]
PHST- 2021/07/05 10:13 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/06 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.687374 [doi]
PST - epublish
SO  - Front Oncol. 2021 Jun 18;11:687374. doi: 10.3389/fonc.2021.687374. eCollection 
      2021.